Overcoming the skin barrier properties efficiently, temporarily, and safely for successful transdermal drug delivery remains a challenge. We synthesized three series of potential skin permeation enhancers derived from natural amino acid derivatives proline, 4-hydroxyproline, and pyrrolidone carboxylic acid, which is a component of natural moisturizing factor. Permeation studies using in vitro human skin identified dodecyl prolinates with N-acetyl, propionyl, and butyryl chains (Pro2, Pro3, and Pro4, respectively) as potent enhancers for model drugs theophylline and diclofenac. The proline derivatives were generally more active than 4-hydroxyprolines and pyrrolidone carboxylic acid derivatives. Pro2-4 had acceptable in vitro toxicities on 3T3 fibroblast and HaCaT cell lines with IC50 values in tens of µM. Infrared spectroscopy using the human stratum corneum revealed that these enhancers preferentially interacted with the skin barrier lipids and decreased the overall chain order without causing lipid extraction, while their effects on the stratum corneum protein structures were negligible. The impacts of Pro3 and Pro4 on an in vitro transepidermal water loss and skin electrical impedance were fully reversible. Thus, proline derivatives Pro3 and Pro4 have an advantageous combination of high enhancing potency, low cellular toxicity, and reversible action, which is important for their potential in vivo use as the skin barrier would quickly recover after the drug/enhancer administration is terminated.

• MeSH
• Administration, Cutaneous MeSH
• Hydroxyproline metabolism   MeSH
• Skin Absorption * MeSH
• Skin metabolism   MeSH
• Carboxylic Acids metabolism   MeSH
• Pharmaceutical Preparations metabolism   MeSH
• Humans MeSH
• Organic Chemicals metabolism   MeSH
• Permeability MeSH
• Proline * metabolism   MeSH
• Pyrrolidinones pharmacology   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Hydroxyproline MeSH
• Carboxylic Acids MeSH
• Pharmaceutical Preparations MeSH
• Organic Chemicals MeSH
• Proline * MeSH
• Pyrrolidinones MeSH

PURPOSE: To study new skin penetration/permeation enhancers based on amphiphilic galactose derivatives. METHODS: Two series of alkyl and alkenyl galactosides were synthesized and evaluated for their enhancing effect on transdermal/topical delivery of theophylline (TH), hydrocortisone (HC) and cidofovir (CDV), reversibility of their effects on transepidermal water loss (TEWL) and skin impedance, interaction with the stratum corneum using infrared spectroscopy, and cytotoxicity on keratinocytes and fibroblasts. RESULTS: Initial evaluation identified 1-(α-D-galactopyranosyl)-(2E)-pentadec-2-ene A15 as a highly potent enhancer - it increased TH and HC flux through human skin 8.5 and 5 times, respectively. Compound A15 increased the epidermal concentration of a potent antiviral CDV 7 times over that reached by control and Span 20 (an established sugar-based enhancer). Infrared spectroscopy of human stratum corneum indicated interaction of A15 with skin barrier lipids but not proteins. These effects of A15 on the skin barrier were reversible (both TEWL and skin impedance returned to baseline values within 24 h after A15 had been removed from skin). In vitro toxicity of A15 on HaCaT keratinocytes and 3T3 fibroblasts was acceptable, with IC50 values over 60 μM. CONCLUSIONS: Galactosyl pentadecene A15 is a potent enhancer with low toxicity and reversible action.

• Keywords
• galactoside, penetration enhancers, sugar, topical drug delivery, transdermal drug delivery,
• MeSH
• Alkenes administration & dosage   chemistry   MeSH
• Administration, Cutaneous MeSH
• Cidofovir MeSH
• Cytosine administration & dosage   analogs & derivatives   chemistry   MeSH
• Epidermis metabolism   MeSH
• Fibroblasts drug effects   metabolism   MeSH
• Galactose analogs & derivatives   chemistry   MeSH
• Galactosides administration & dosage   chemistry   MeSH
• Hydrocortisone administration & dosage   chemistry   MeSH
• Keratinocytes drug effects   metabolism   MeSH
• Skin Absorption drug effects   MeSH
• Skin metabolism   MeSH
• Humans MeSH
• Lipids chemistry   MeSH
• Organophosphonates administration & dosage   chemistry   MeSH
• Permeability MeSH
• Theophylline administration & dosage   chemistry   MeSH
• Drug Liberation MeSH
• Water MeSH
• Structure-Activity Relationship MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Names of Substances
• Alkenes MeSH
• Cidofovir MeSH
• Cytosine MeSH
• Galactose MeSH
• Galactosides MeSH
• Hydrocortisone MeSH
• Lipids MeSH
• Organophosphonates MeSH
• Theophylline MeSH
• Water MeSH

PURPOSE: In this work, we investigate prodrug and enhancer approaches for transdermal and topical delivery of antiviral drugs belonging to the 2,6-diaminopurine acyclic nucleoside phosphonate (ANP) group. Our question was whether we can differentiate between transdermal and topical delivery, i.e., to control the delivery of a given drug towards either systemic absorption or retention in the skin. METHODS: The in vitro transdermal delivery and skin concentrations of seven antivirals, including (R)- and (S)-9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine (PMPDAP), (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine ((S)-HPMPDAP), its 8-aza analog, and their cyclic and hexadecyloxypropyl (HDP) prodrugs, was investigated with and without the penetration enhancer dodecyl-6-(dimethylamino)hexanoate (DDAK) using human skin. RESULTS: The ability of ANPs to cross the human skin barrier was very low (0.5-1.4 nmol/cm(2)/h), and the majority of the compounds were found in the stratum corneum, the uppermost skin layer. The combination of antivirals and the penetration enhancer DDAK proved to be a viable approach for transdermal delivery, especially in case of (R)-PMPDAP, an anti-HIV effective drug (30.2 ± 2.3 nmol/cm(2)/h). On the other hand, lysophospholipid-like HDP prodrugs, e.g., HDP-(S)-HPMPDAP, reached high concentrations in viable epidermis without significant systemic absorption. CONCLUSIONS: By using penetration enhancers or lysolipid prodrugs, it is possible to effectively target systemic diseases by the transdermal route or to target cutaneous pathologies by topical delivery.

• MeSH
• 2-Aminopurine administration & dosage   analogs & derivatives   chemistry   MeSH
• Antiviral Agents administration & dosage   chemistry   MeSH
• Administration, Cutaneous MeSH
• Skin Absorption drug effects   physiology   MeSH
• Drug Delivery Systems methods   MeSH
• Humans MeSH
• Liposomes MeSH
• Organ Culture Techniques MeSH
• Prodrugs administration & dosage   chemistry   MeSH
• Check Tag
• Humans MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• 2-Aminopurine MeSH
• 2,6-diaminopurine MeSH Browser
• Antiviral Agents MeSH
• Liposomes MeSH
• Prodrugs MeSH

PURPOSE: Acyclic nucleoside phosphonates possess unique antiviral and antineoplastic activities; however, their polar phosphonate moiety is associated with low ability to cross biological membranes. We explored the potential of transdermal and topical delivery of 2,6-diaminopurine derivative cPr-PMEDAP. METHODS: In vitro diffusion of cPr-PMEDAP was investigated using formulations at different pH and concentration and with permeation enhancer through porcine and human skin. RESULTS: Ability of 0.1-5% cPr-PMEDAP to cross human skin barrier was very low with flux values ~40 ng/cm(2)/h, the majority of compound found in the stratum corneum. The highest permeation rates were found at pH 6; increased donor concentration had no influence. The permeation enhancer dodecyl 6-dimethylaminohexanoate (DDAK, 1%) increased flux of cPr-PMEDAP (up to 61 times) and its concentration in nucleated epidermis (up to ~0.5 mg of cPr-PMEDAP/g of the tissue). No deamination of cPr-PMEDAP into PMEG occurred during permeation studies, but N-dealkylation into PMEDAP mediated by skin microflora was observed. CONCLUSIONS: Transdermal or topical application of cPr-PMEDAP enabled by the permeation enhancer DDAK may provide an attractive alternative route of administration of this potent antitumor and antiviral compound.

• MeSH
• Adenine administration & dosage   MeSH
• Antiviral Agents administration & dosage   MeSH
• Administration, Cutaneous MeSH
• Dimethylamines MeSH
• Dodecanol MeSH
• Caproates metabolism   MeSH
• Hydrogen-Ion Concentration MeSH
• Skin metabolism   MeSH
• Humans MeSH
• Methylamines metabolism   MeSH
• Organophosphonates administration & dosage   MeSH
• Permeability MeSH
• Swine MeSH
• Antineoplastic Agents administration & dosage   MeSH
• Animals MeSH
• Check Tag
• Humans MeSH
• Animals MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Names of Substances
• Adenine MeSH
• Antiviral Agents MeSH
• Dimethylamines MeSH
• dodecyl 6-(dimethylamino)hexanoate MeSH Browser
• Dodecanol MeSH
• Caproates MeSH
• Methylamines MeSH
• N(6)-cyclopropyl-9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine MeSH Browser
• Organophosphonates MeSH
• Antineoplastic Agents MeSH